Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir.
Alosaimi B, Alshanbari HM, Alturaiqy M, AlRawi HZ, Alamri S, Albujaidy A, Bin Sabaan A, Alrashed AA, Alamer A, Alghofaili F, Al-Duraymih K, Alshalani AJ, Alturaiki W. Alosaimi B, et al. Among authors: alrashed aa. Pharmaceuticals (Basel). 2022 Nov 24;15(12):1456. doi: 10.3390/ph15121456. Pharmaceuticals (Basel). 2022. PMID: 36558907 Free PMC article.
Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis.
Alamer A, Alrashed AA, Alfaifi M, Alosaimi B, AlHassar F, Almutairi M, Howaidi J, Almutairi W, Mohzari Y, Sulaiman T, Al-Jedai A, Alajami HN, Alkharji F, Alsaeed A, Alali AH, Baredhwan AA, Abraham I, Almulhim AS. Alamer A, et al. Among authors: alrashed aa. Curr Med Res Opin. 2021 Jul;37(7):1085-1097. doi: 10.1080/03007995.2021.1920900. Epub 2021 May 19. Curr Med Res Opin. 2021. PMID: 33890544 Free PMC article.
Severity of COVID-19 infection in ACEI/ARB users in specialty hospitals: A retrospective cohort study.
Alrashed AA, Khan TM, Alhusseini NK, Asdaq SMB, Enani M, Alosaimi B, Alkhani NM, Mohzari Y, Alghalbi MM, Alfahad W, Alanazi MA, Albujaidya AS, Ben-Akresh A, Almutairi M, Abraham I, Alamer A. Alrashed AA, et al. J Infect Public Health. 2021 Jun;14(6):726-733. doi: 10.1016/j.jiph.2021.03.004. Epub 2021 Mar 23. J Infect Public Health. 2021. PMID: 34020213 Free PMC article.
Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades.
Imran M, Asdaq SMB, Khan SA, Unnikrishnan Meenakshi D, Alamri AS, Alsanie WF, Alhomrani M, Mohzari Y, Alrashed A, AlMotairi M, Alkhaldi EH, Alorabi AK, Alshrari AS, Tauseef M, Abida, Alaqel SI, Alam O, Bakht MA. Imran M, et al. Pharmaceuticals (Basel). 2021 Jul 22;14(8):710. doi: 10.3390/ph14080710. Pharmaceuticals (Basel). 2021. PMID: 34451807 Free PMC article. Review.
Early oral switch to combined cefixime therapy for management of osteoarticular infections in pediatric sickle cell disease patients: A descriptive analysis.
Mohzari YA, Alshuraim R, Asdaq SMB, Aljobair F, Alrashed A, Alsowaida YS, Alamer A, Al Munjem MF, Al Musawa MI, Hatata M, Alzaaqi MA, Binrokan A, Alajlan SA, Abraham I, Alamer A. Mohzari YA, et al. J Infect Public Health. 2022 Jan;15(1):1-6. doi: 10.1016/j.jiph.2021.11.006. Epub 2021 Nov 17. J Infect Public Health. 2022. PMID: 34852307 Free article.
52 results